Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02183389
Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Linagliptin, high doseDrug: Linagliptin, low doseDrug: Linagliptin, medium dose
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02183480
Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 715
- Registration Number
- NCT02183701
Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT02183376
A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02183116
Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02183649
Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
Phase 3
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 192
- Registration Number
- NCT02183168
Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 91
- Registration Number
- NCT02183129
Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT02183467
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BI 1356 BS - single rising doseDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT02183350